KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbCellera Biologics (ABCL) EBITDA Margin (2020 - 2026)

AbCellera Biologics filings provide 7 years of EBITDA Margin readings, the most recent being 497.29% for Q1 2026.

  • Quarterly EBITDA Margin rose 64181.0% to 497.29% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 175.97% through Mar 2026, up 57268.0% year-over-year, with the annual reading at 194.69% for FY2025, 37936.0% up from the prior year.
  • EBITDA Margin hit 497.29% in Q1 2026 for AbCellera Biologics, down from 23.37% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 53.41% in Q1 2022 and bottomed at 1139.1% in Q1 2025.
  • Average EBITDA Margin over 5 years is 386.09%, with a median of 408.94% recorded in 2024.
  • Peak annual rise in EBITDA Margin hit 71636bps in 2025, while the deepest fall reached -73016bps in 2025.
  • AbCellera Biologics' EBITDA Margin stood at 141.88% in 2022, then crashed by -264bps to 516.51% in 2023, then plummeted by -43bps to 739.72% in 2024, then surged by 97bps to 23.37% in 2025, then crashed by -2028bps to 497.29% in 2026.
  • Per Business Quant, the three most recent readings for ABCL's EBITDA Margin are 497.29% (Q1 2026), 23.37% (Q4 2025), and 638.3% (Q3 2025).